The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Randomized study of ASTX727 with or without iadademstat in accelerated/blast-phase MPNs
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses a randomized study (NCT06661915) of ASTX727 with or without iadademstat in accelerated/blast-phase myeloproliferative neoplasms (MPNs), highlighting the poor outcomes observed when treating patients with acute myeloid leukemia (AML)-based regimens. Dr Patel explains that the study aims to evaluate the efficacy of this combination, with primary endpoints including rates of acute leukemia response-complete (ALR-C) within four cycles of therapy. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
